论文部分内容阅读
目的:评价达立通与“三联”疗法对根除慢性胃炎患者幽门螺旋杆菌(Hp)感染的临床疗效。方法:选取2015年11月—2016年11月间收治的慢性胃炎Hp感染患者90例临床资料,将其分为治疗组和对照组,每组45例;对照组患者给予“三联”疗法(雷贝拉唑肠溶片、克拉霉素、阿莫西林)治疗,治疗组患者在对照组基础上加用达立通治疗;比较两组患者治疗后的Hp清除率,不良反应的发生率和临床症状评分值的变化情况。结果:治疗前,两组患者临床症状评分值经组间比较其差异无统计学意义(P>0.05),治疗后治疗组患者症状评分值优于对照组(P<0.05);治疗组患者治疗后Hp根除率为91.10%高于对照组为71.11%(P<0.05),不良反应的发生率为4.44%低于对照组为17.78%(P<0.05)。结论:采用达立通与“三联”疗法治疗慢性胃炎Hp感染患者,增强临床疗效,提高了致病菌的清除率。
Objective: To evaluate the clinical efficacy of Dalitong and triple therapy in the eradication of Helicobacter pylori (Hp) infection in patients with chronic gastritis. Methods: The clinical data of 90 patients with Hp infection of chronic gastritis admitted from November 2015 to November 2016 were selected and divided into treatment group and control group, with 45 patients in each group. Patients in the control group were treated with “triple therapy” (Rabeprazole enteric-coated tablets, clarithromycin, amoxicillin) treatment, the treatment group in addition to the control group based on the use of daritason treatment; compared Hp clearance rate after treatment in both groups, the incidence of adverse reactions And clinical symptom score value changes. Results: Before treatment, clinical symptom scores of the two groups had no significant difference (P> 0.05), but the score of symptom score of the treatment group was better than that of the control group (P <0.05) The Hp eradication rate was 91.10% higher than that of the control group (71.11%, P <0.05). The incidence of adverse reactions was 4.44% lower than that of the control group (17.78%, P <0.05). Conclusion: The treatment of patients with Hp infection of chronic gastritis by dalitong and triple therapy can enhance clinical curative effect and increase the clearance rate of pathogenic bacteria.